Search

Neil D Moorcroft

from Bloomsbury, NJ
Age ~49
Get Report
Also known as:
Neil D Moorcrof, Jennifer Moorcroft, Neil F
Related to:
Lorraine Susan MoorcroftJennifer E Moorcroft, 47
Connected to:
Eric S Moorcroft, 52Helen L Moorcroft, 109Kelly E Moorcroft, 55Raymond L Moorcroft, 71Scott J Moorcroft, 52Sharon L Moorcroft, 79Sherrie G Moorcroft, 48Shirley Moorcroft, 60Dellie L Moordigian, 86A Moore

Neil Moorcroft Phones & Addresses

  • Bloomsbury, NJ
  • Renick, WV
  • Princeton, NJ
  • Stewartsville, NJ
  • 37 Edgewood Rd, Bedminster, NJ 07921
  • Bowling Green, KY
  • Warren, NJ
  • 603 State Route 173, Bloomsbury, NJ 08804

Education

Degree: High school graduate or higher

Resumes

Resumes

Neil Moorcroft Photo 1

Positions Leading To Manager Of Quality Assurance

View page
Location:
603 Rte #173, Bloomsbury, NJ
Industry:
Pharmaceuticals
Work:
Dsm 2015 - 2016
Positions Leading To Quality Supervisor ??? Stability
Flowmetric, Inc 2015 - 2016
Positions Leading To Manager of Quality Assurance
Chromocell Corporation 2013 - 2015
Positions Leading To Assistant Director Natural Products and Analytical Chemistry
Maxsar Biopharma Jan 2012 - Jan 2013
Drug Discovery Scientist - Platform Development
Sanofi 2000 - 2012
Positions Leading To Research Investigator
Education:
King's College London 1999 - 2001
Master of Science, Masters University of Greenwich 1994 - 1999
Bachelors, Bachelor of Science, Chemistry
Skills:
Drug Discovery
Analytical Chemistry
Medicinal Chemistry
Immunology
Elisa
Oncology
Organic Synthesis
Chromatography
Cell Culture
Flow Cytometry
Cross Functional Team Leadership
Cell Biology
Laboratory Automation
Problem Solving
In Vitro Assays
Microwave Synthesis
Multi Dimensional Analysis
Phenotypic Screen
Lead Optimization
Project Team Leader
Supervisory Experience
Hazmat
Heterocyclic Chemistry
Cell Sorting
Safety Leader
Research Investigator
Drug Optimization
Cell Differentiation
Primary Cell Culture
Project Collaboration
Innovative Thinking
Project Mentor
Central Nervous System
Inflammation
Target Analysis
Project Management
Transition Metal Catalysis
Analytical Abilities
Parallel Synthesis
Target Validation
Synthetic Chemistry
Scientist
Autoimmune Diseases
Synthetic Routes
Hplc Ms
Lcms
Scientific Communications
Medical Writing
Drive To Achieve
Deadline Driven
Languages:
English
French
Neil Moorcroft Photo 2

Neil Moorcroft

View page
Neil Moorcroft Photo 3

Neil Moorcroft

View page

Publications

Us Patents

Substituted Aza-Indoles As Inhibitors Of Poly(Adp-Ribose) Polymerase (Parp)

View page
US Patent:
8008491, Aug 30, 2011
Filed:
Jun 17, 2008
Appl. No.:
12/140632
Inventors:
John Ziqi Jiang - Hillsborough NJ, US
Jack Roger Koehl - Whitehouse Station NJ, US
Shujaath Mehdi - Manville NJ, US
Neil Moorcroft - Bloomsbury NJ, US
Kwon Yon Musick - Raritan NJ, US
Philip Marvin Weintraub - Warren NJ, US
Paul Robert Eastwood - Barcelona, ES
Assignee:
Aventis Pharmaceuticals, Inc. - Bridgewater NJ
International Classification:
C07D 403/04
C07D 209/04
US Classification:
544373, 548465, 548466, 548467, 548483
Abstract:
The present invention relates to a series of substituted aza-indole derivatives of the formula I:.

Substituted Pyridones As Inhibitors Of Poly(Adp-Ribose) Polymerase (Parp)

View page
US Patent:
8173682, May 8, 2012
Filed:
Sep 26, 2006
Appl. No.:
11/535127
Inventors:
Philip M. Weintraub - Warren NJ, US
Paul R. Eastwood - Barcelona, ES
Shujaath Mehdi - Manville NJ, US
David W. Stefany - Hillsborough NJ, US
Kwon Yon Musick - Bridgewater NJ, US
Neil Moorcroft - Bloomsbury NJ, US
Sungtaek Lim - Flemington NJ, US
John Z. Jiang - Hillsborough NJ, US
Hartmut Rutten - Idstein, DE
Stefan Peukert - Frankfurt, DE
Uwe Schwahn - Sulzbach, DE
Assignee:
Aventis Pharmaceuticals Inc. - Bridgewater NJ
International Classification:
A61K 31/4436
C07D 401/14
US Classification:
514343, 5462784, 5462787
Abstract:
The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I:.

Substituted Indoles As Inhibitors Of Poly (Adp-Ribose) Polymerase (Parp)

View page
US Patent:
20050054631, Mar 10, 2005
Filed:
Sep 1, 2004
Appl. No.:
10/933098
Inventors:
John Jiang - Hillsborough NJ, US
Jack Koehl - Whitehouse Station NJ, US
Shujaath Mehdi - Manville NJ, US
Neil Moorcroft - Bloomsbury NJ, US
Kwon Musick - Raritan NJ, US
Philip Weintraub - Warren NJ, US
Paul Eastwood - Barcelona, ES
Assignee:
Aventis Pharmaceuticals Inc. - Bridgewater NJ
International Classification:
A61K031/55
A61K031/541
A61K031/5377
A61K031/503
A61K031/496
A61K031/4745
US Classification:
514210210, 514248000, 514217070, 514217090, 514227800, 514234200, 514253040, 514300000
Abstract:
The present invention relates to a series of substituted indole derivatives of the formula I:

5-Aryl-Pyrazolo[4,3-D]Pyrimidines, Pyridines, And Pyrazines And Related Compounds

View page
US Patent:
20050070542, Mar 31, 2005
Filed:
Sep 3, 2004
Appl. No.:
10/933700
Inventors:
Kevin Hodgetts - Kilingworth CT, US
Stanly John - Basking Ridge NJ, US
Neil Moorcroft - Bloomsbury NJ, US
Greg Shutske - Pittstown NJ, US
Bernd Kaiser - Wallingford CT, US
Yasuchika Yamaguchi - Guilford CT, US
Ping Ge - Durham CT, US
Raymond Horvath - Guilford CT, US
International Classification:
A61K031/53
A61K031/519
C07D487/02
US Classification:
514243000, 514261100, 514260100, 514262100, 544184000, 544262000
Abstract:
5-aryl-Pyrazolo[4,3-d]pyrimidines, 6-aryl-Pyrazolo[3,4-d]pyrimidines and related compounds, as well as other chemically related compounds, that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Heteroaryl Fused Pyridines, Pyrazines And Pyrimidines As Crf1 Receptor Ligands

View page
US Patent:
20050113379, May 26, 2005
Filed:
Sep 3, 2004
Appl. No.:
10/933834
Inventors:
Ping Ge - Durham CT, US
Raymond Horvath - Guilford CT, US
Lu Yan Zhang - Branford CT, US
Yasuchika Yamaguchi - Guilford CT, US
Bernd Kaiser - Wallingford CT, US
Xuechun Zhang - Branford CT, US
Suoming Zhang - Madison CT, US
He Zhao - Branford CT, US
Stanly John - Basking Ridge NJ, US
Neil Moorcroft - Bloomsbury NJ, US
Greg Shutske - Pittstown NJ, US
International Classification:
A61K031/519
A61K031/522
C07D498/02
C07D491/02
C07D473/02
US Classification:
514249000, 514260100, 514262100, 514263300, 544255000, 544262000, 544265000, 544350000
Abstract:
Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Azacarboline Derivatives, Preparation Method Thereof And Therapeutic Use Of Same

View page
US Patent:
20110178053, Jul 21, 2011
Filed:
Jun 11, 2009
Appl. No.:
12/997326
Inventors:
Christopher Arendt - Bridgewater NJ, US
Didier Babin - Paris, FR
Olivier Bedel - Paris, FR
Thierry Gouyon - Paris, FR
Mikhail Levit - Bridgewater NJ, US
Ronghua Li - Bridgewater NJ, US
Serge Mignani - Paris, FR
Neil Moorcroft - Bridgewater NJ, US
David Papin - Paris, FR
Assignee:
SANOFI-AVENTIS - Paris
International Classification:
A61K 31/555
C07D 403/14
A61K 31/496
C07D 471/14
A61K 31/4375
C07D 413/14
A61K 31/5377
C07D 401/14
A61K 31/551
A61K 31/506
C07F 9/92
A61P 35/00
US Classification:
514189, 544361, 51425303, 546 82, 514293, 544126, 5142328, 540575, 514218, 544316, 514274, 546 4
Abstract:
The invention relates to novel azacarbonlines having formula (I), wherein: R3, R4 represent independently H; hal; CF; substituted oxy, optionally substituted alkoxy; optionally substituted amino; substituted carbonyl; optionally substituted carboxyl; optionally substituted amide; sulphur, such as optionally substituted sulphones, sulphoxides or sulphides; linear, branched or cyclic C-Calkyl optionally comprising an optionally substituted heteroatom; optionally substituted linear, branched or cyclic C-Calkenyl; optionally substituted linear or branched C-Calkynyl; optionally substituted aryl or heteroaryl; of which may be optionally substituted; in the form of a base or an acid addition salt. The invention also relates to the use of same in therapeutics for the treatment of cancer and to synthesis methods.

Substituted Pyridones As Inhibitors Of Poly(Adp-Ribose) Polymerase (Parp)

View page
US Patent:
20120202795, Aug 9, 2012
Filed:
Apr 18, 2012
Appl. No.:
13/449711
Inventors:
Philip M. WEINTRAUB - Warern NJ, US
Paul R. EASTWOOD - RUBI Barcelona, ES
Shujaath MEHDI - Manville NJ, US
David W. STEFANY - Hillsborough NJ, US
Kwon Yon MUSICK - Bridgewater NJ, US
Neil MOORCROFT - Bloomsbury NJ, US
Sungtaek LIM - Flemington NJ, US
John Z. JIANG - Hillsborough NJ, US
Hartmut RUTTEN - Idstein, DE
Stefan PEUKERT - Arlington MA, US
Uwe SCHWAHN - Sulzbach, DE
Assignee:
AVENTIS PHARMACEUTICALS INC. - Bridgewater NJ
International Classification:
A61K 31/4412
C07D 217/24
C07D 413/10
C07D 401/10
C07D 401/04
C07D 413/04
C07D 405/04
C07D 409/04
C07D 409/14
C07D 413/14
C07D 405/14
A61K 31/506
C07D 491/113
C07D 417/14
A61K 31/496
A61K 31/5377
A61K 31/4545
A61K 31/551
A61K 31/497
A61P 25/00
A61P 25/28
A61P 9/10
A61P 9/00
A61K 31/472
A61K 31/444
C07D 213/64
US Classification:
514218, 546300, 546141, 544131, 5462724, 5462694, 5462834, 5462804, 544364, 546187, 540575, 544405, 51425218, 544295, 544331, 546 19, 546256, 51425311, 514351, 5142355, 514316, 51425505, 514275, 514309, 514333
Abstract:
The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I:wherein R, R, R, Rand Rare as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
Control profile
Neil D Moorcroft from Bloomsbury, NJ, age ~49 Get Report